- Home
- LLYVK vs STVN Comparison
LLYVK vs STVN Comparison
Compare LLYVK & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVK
- STVN
- Stock Information
- Founded
- LLYVK 1991
- STVN 1949
- Country
- LLYVK United States
- STVN Italy
- Employees
- LLYVK N/A
- STVN N/A
- Industry
- LLYVK Broadcasting
- STVN Containers/Packaging
- Sector
- LLYVK Industrials
- STVN Consumer Discretionary
- Exchange
- LLYVK Nasdaq
- STVN Nasdaq
- Market Cap
- LLYVK 6.3B
- STVN 6.2B
- IPO Year
- LLYVK N/A
- STVN 2021
- Fundamental
- Price
- LLYVK $69.00
- STVN $20.64
- Analyst Decision
- LLYVK
- STVN Buy
- Analyst Count
- LLYVK 0
- STVN 6
- Target Price
- LLYVK N/A
- STVN $27.50
- AVG Volume (30 Days)
- LLYVK 359.3K
- STVN 400.0K
- Earning Date
- LLYVK 01-01-0001
- STVN 11-05-2024
- Dividend Yield
- LLYVK N/A
- STVN 0.28%
- EPS Growth
- LLYVK N/A
- STVN N/A
- EPS
- LLYVK N/A
- STVN 0.48
- Revenue
- LLYVK N/A
- STVN $1,220,254,294.00
- Revenue This Year
- LLYVK N/A
- STVN $3.01
- Revenue Next Year
- LLYVK $10.07
- STVN $7.16
- P/E Ratio
- LLYVK N/A
- STVN $43.28
- Revenue Growth
- LLYVK N/A
- STVN 3.53
- 52 Week Low
- LLYVK $33.50
- STVN $16.56
- 52 Week High
- LLYVK $73.89
- STVN $34.73
- Technical
- Relative Strength Index (RSI)
- LLYVK 50.93
- STVN 47.10
- Support Level
- LLYVK $67.37
- STVN $19.25
- Resistance Level
- LLYVK $72.28
- STVN $23.95
- Average True Range (ATR)
- LLYVK 1.84
- STVN 1.09
- MACD
- LLYVK -1.02
- STVN -0.01
- Stochastic Oscillator
- LLYVK 25.89
- STVN 24.60
About LLYVK Liberty Media Corporation Series C Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's strategy for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.